河马信号通路
可药性
泛素
结直肠癌
激酶
癌症研究
化学
医学
癌症
内科学
生物化学
基因
作者
Dorothy Benton,Jonathan Chernoff
标识
DOI:10.1016/j.chembiol.2023.06.023
摘要
In this issue of Cell Chemical Biology, Liu et al. 1 Liu Y.X. Wan S. Yang X.Q. Wang Y. Gan W.J. Ye W.L. He X.S. Chen J.J. Yang Y. Yang X.M. et al. TRIM21 is a druggable target for the treatment of metastatic colorectal cancer through ubiquitination and activation of MST2. Cell Chem. Biol. 2023; 30: 709-725.e6https://doi.org/10.1016/j.chembiol.2023.05.009 Abstract Full Text Full Text PDF Scopus (1) Google Scholar identify TRIM21-mediated ubiquitination of the Hippo pathway kinase MST2, promoting its dimerization and activation. The antidepressant Vilazodone was found to bind to TRIM21, enhancing its activity toward MST2, increasing Hippo activation, and reducing colorectal cancer metastasis. In this issue of Cell Chemical Biology, Liu et al. 1 Liu Y.X. Wan S. Yang X.Q. Wang Y. Gan W.J. Ye W.L. He X.S. Chen J.J. Yang Y. Yang X.M. et al. TRIM21 is a druggable target for the treatment of metastatic colorectal cancer through ubiquitination and activation of MST2. Cell Chem. Biol. 2023; 30: 709-725.e6https://doi.org/10.1016/j.chembiol.2023.05.009 Abstract Full Text Full Text PDF Scopus (1) Google Scholar identify TRIM21-mediated ubiquitination of the Hippo pathway kinase MST2, promoting its dimerization and activation. The antidepressant Vilazodone was found to bind to TRIM21, enhancing its activity toward MST2, increasing Hippo activation, and reducing colorectal cancer metastasis. TRIM21 is a druggable target for the treatment of metastatic colorectal cancer through ubiquitination and activation of MST2Liu et al.Cell Chemical BiologyJune 23, 2023In BriefLiu et al. report that TRIM21 inhibits colorectal cancer (CRC) invasion and metastasis by activating Hippo signaling. Furthermore, the authors identify an antidepressant, vilazodone, which directly binds to TRIM21 and has significant anti-metastatic effects on CRC. These results suggest that TRIM21 is a promising drug target for metastatic CRC. Full-Text PDF
科研通智能强力驱动
Strongly Powered by AbleSci AI